IMMUNOPHARMA AS

Operating

ImmunoPharma — Research-based company targeting immune stimulating substances

Utvikle, distribuere og selge ernæringsprodukter og farmasøytiske produkter samt tilknyttede tjenester med mer, samt investering i annen virksomhet.

Keywords

advertising businesscreative businessproductionadvertising materialarrangementimplementationadvertising campaignsdesignplacementadvertisementsnewspapersmagazinesradio and televisioninternetoutdoor advertisingbillboardsposterswindow displayinterior designshowroomscarsbusesaerial advertisingdistributiondeliverypromotional materialsamplesprocurementracksmarketing campaignsmarketing consultancy

Organization

Chairman of the board: KR
Kjetil Ramsøy1971
Years since formation: 16 years; since Jan 4, 2010
Type: Limited company
VAT registered: Yes
Number of employees: 15

Ownership

Number of shares and share classes: 138,654,422; 1 share class
Total number of shareholders: 57; 32 companies, 25 persons
Belongs to group of

Financials

Total operating income 2025: 18,004,610; NOK
Annual total result 2025: -4,514,135; NOK
Total equity 2025: 204,510,579; NOK

Last update: Jul 15, 2026

Management

Board

Name	Role	Shares
KR Kjetil Ramsøy 1971	Chairman	-
FM Frode Marc Bohan 1968	Board Member	-
PJ Piotr Jerzy Sierdzinski 1978	Alternate Member	-

Others

Name	Role	Shares
F FORVIS MAZARS AS	Auditor	-

Top 10 individual shareholders

Name	Role	Shares
MB Marc Bohan Frode 1968	-	35.45 % indirectly
ØK Øien Kim 1968	-	28.9 % indirectly
TS Thorsheim Sjur 1958	-	1.6 % indirectly
NF Normann Fjøs Henning 1965	-	1.44 % indirectly
CE Christian Espeseth Knut 1965	-	1.23 % indirectly

Last update: Jan 22, 2026

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
B BOHAN & CO AS	Ordinary shares	49,146,837	35.45 %
N NICOLINE INVEST AS	Ordinary shares	40,068,866	28.9 %
A AURORA NORDIC AS	Ordinary shares	2,673,697	1.93 %
P PRO AS	Ordinary shares	2,222,222	1.6 %
T THEO INVESTMENTS AS	Ordinary shares	2,144,444	1.55 %
N NOXA AS	Ordinary shares	2,000,000	1.44 %
V VESTMARK RESEARCH CONSULTING AS	Ordinary shares	2,000,000	1.44 %
3 3LP NORGE AS	Ordinary shares	1,724,901	1.24 %
R RHUMB LINE AS	Ordinary shares	1,685,492	1.22 %
M MOMENTUM CONSULT & INVEST AS	Ordinary shares	1,000,000	0.72 %
OV Ole Vrenne Stein 1966	Ordinary shares	1,000,000	0.72 %
FN Flatner Nicolai 1969	Ordinary shares	777,777	0.56 %
C CINCO INVEST AS	Ordinary shares	750,000	0.54 %
E ENG AS	Ordinary shares	741,250	0.53 %
P PVO INVEST AS	Ordinary shares	666,666	0.48 %
L LT FINANS AS	Ordinary shares	500,000	0.36 %
BØ Bjørkmann Ødven Kjetil 1972	Ordinary shares	445,000	0.32 %
J JAN FR. BJERKENES HOLDING AS	Ordinary shares	444,444	0.32 %
L LANDMARK INVEST AS	Ordinary shares	350,000	0.25 %
MM Morten Mortensen Roger 1967	Ordinary shares	333,333	0.24 %
NT Nielsen Trygve 1964	Ordinary shares	333,333	0.24 %
I IMMUNOPHARMA AS	Ordinary shares	275,000	0.2 %
C CARUSO HOLDING AS Closed	Ordinary shares	267,858	0.19 %
T TEAM6 AS	Ordinary shares	250,000	0.18 %
M MIL INVEST AS	Ordinary shares	222,222	0.16 %
L LJM AS	Ordinary shares	222,222	0.16 %
K KLEIVO HOLDING AS	Ordinary shares	150,000	0.11 %
H HELM STYRBORD AS	Ordinary shares	142,000	0.1 %
JJ Jacob Jebsen Vincent 1944	Ordinary shares	133,929	0.1 %
VL Vitali-Rosati Ludovico-Enrico 1962	Ordinary shares	133,929	0.1 %
FR Femdal Røe Vidar 1968	Ordinary shares	133,929	0.1 %
R RED GRUPPEN AS	Ordinary shares	111,111	0.08 %
HO Hansen Ole 1965	Ordinary shares	111,111	0.08 %
G GRANSJØEN AS	Ordinary shares	111,111	0.08 %
N Nest Trading A/S	Ordinary shares	102,200	0.07 %
TN Toralf Nilsen Inge 1961	Ordinary shares	100,000	0.07 %
H HIPPOGRIFF AS	Ordinary shares	100,000	0.07 %
AN Arthur Neset Kjell 1961	Ordinary shares	76,700	0.06 %
NT Nesheim Trond 1969	Ordinary shares	56,049	0.04 %
V VANGEN BIL AS	Ordinary shares	50,000	0.04 %
GS Grende Stein 1952	Ordinary shares	50,000	0.04 %
ET Erikstad Terje 1984	Ordinary shares	41,595	0.03 %
LS Lude Sande Haakon 1978	Ordinary shares	40,000	0.03 %
K K&S INVEST AS	Ordinary shares	37,500	0.03 %
AS Arnar Sigfusson Ingolfur 1955	Ordinary shares	36,600	0.03 %
JG Johan Grytten Leidulv 1948	Ordinary shares	35,000	0.03 %
LM Lambrechts Marit 1957	Ordinary shares	34,638	0.02 %
R RYSSEVIK INVEST LTD NUF	Ordinary shares	23,266	0.02 %
VE Vatne Erlend 1972	Ordinary shares	22,222	0.02 %
EC Emilie Charlotte Jandl Von Hall Diana 1970	Ordinary shares	20,000	< 0.01 %
TM Tveite Magnar 1964	Ordinary shares	17,086	< 0.01 %
RL Rebecca Laishley Sandbu Maria 1983	Ordinary shares	12,000	< 0.01 %
C CAPTIVIA FINANS AS	Ordinary shares	11,000	< 0.01 %
LT Ljones Torgrim 1938	Ordinary shares	10,000	< 0.01 %
OR Oliver Ramsøy Godø Marius 1990	Ordinary shares	9,000	< 0.01 %
SH Strøm-Pedersen Hannah 1995	Ordinary shares	9,000	< 0.01 %
G GENZEB LIMITED NUF	Ordinary shares	1	< 0.01 %

Shares owned by the IMMUNOPHARMA AS

Name	Share class	Total number of shares	Share
I IP EQOLOGY HOLDCO AS	Ordinary shares	20,000,000	100 %
N NATTOPHARMA AS	Ordinary shares	350,000	100 %
A AURORA NORDIC AS	Ordinary shares	2,241,918	100 %
M MYCOTECH PHARMA AS	Ordinary shares	110,330,000	97.77 %
S SMARTFISH AS	Ordinary shares	33,695,080	80.21 %
I IMMUNOPHARMA AS	Ordinary shares	275,000	0.2 %

Last update: Sep 25, 2026

Group structure

IMMUNOPHARMA AS
Total operating income 2025: NOK 18,004,610
Operating profit 2025: NOK -20,461,195
Employees: 15

Financials

in NOK

Summary

Year	2025	2024	2023	2022	2021
Total operating income	18,004,610	12,205,647,000	14,110,340	21,058,663	11,478,057
Annual Total Result	-4,514,135	13,723,672,000	-109,703,887	36,733,018	-37,953,672
Total assets	393,197,113	338,081,366,000	267,015,068	367,491,391	358,690,144
Total liabilities	188,686,535	129,056,652,000	71,714,026	62,163,914	102,524,100
Total equity	204,510,579	209,024,714,000	195,301,042	305,327,477	256,166,044

P&L

Year	2025	2024	2023	2022	2021
Total operating income	18,004,610	12,205,647,000	14,110,340	21,058,663	11,478,057
Total operating costs	38,465,806	50,722,916,000	27,078,091	27,740,900	27,617,542
Operating result	-20,461,195	-38,517,269,000	-12,967,751	-6,682,237	-16,139,485
Financial income/costs	15,562,496	57,211,333,000	-87,367,218	42,029,065	-24,949,462
Profit before tax	-4,898,699	18,694,064,000	-100,334,969	35,346,828	-41,088,947
Total tax & extraordinary income/cost	-384,564	4,970,392,000	9,368,918	-1,386,190	-3,135,275
Annual Total Result	-4,514,135	13,723,672,000	-109,703,887	36,733,018	-37,953,672

Balance overview

Year	2025	2024	2023	2022	2021
Total fixed assets	357,297,771	265,392,221,000	201,120,676	359,976,449	314,236,860
Total current assets	35,899,343	72,689,145,000	65,894,392	7,514,942	44,453,284
Total assets	393,197,113	338,081,366,000	267,015,068	367,491,391	358,690,144
Short term debt	188,010,669	128,672,088,000	71,236,949	34,085,452	61,124,698
Long term debt	675,866	384,564,000	477,077	28,078,462	41,399,402
Total liabilities	188,686,535	129,056,652,000	71,714,026	62,163,914	102,524,100
Contributed capital	204,510,579	327,503,068,000	327,503,068	327,825,617	315,549,609
Retained earnings	0	-118,478,354,000	-132,202,026	-22,498,140	-59,383,565
Total equity	204,510,579	209,024,714,000	195,301,042	305,327,477	256,166,044
Total equity and liabilities	393,197,113	338,081,366,000	267,015,068	367,491,391	358,690,144

Classification

21st company classification

BETA

Individual SMB enterprise

IMMUNOPHARMA AS994 924 273

IMMUNOPHARMA AS

Keywords

Links

Organization

Ownership

Financials

Management

Board

Others

Top 10 individual shareholders

Ownership

Company shareholders

Shares owned by the IMMUNOPHARMA AS

Group structure

Financials

Summary

P&L

Balance overview

Classification